These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Defining the role of incretin mimetic therapy in the management of type 2 diabetes. Unger J, Nadeau DA. J Fam Pract; 2007 Dec; 56(12 Suppl New):S4-S10. PubMed ID: 18664341 [Abstract] [Full Text] [Related]
26. Early detection and integrated management of dysglycemia in cardiovascular disease: a key factor for decreasing the likelihood of future events. Anselmino M, Mellbin L, Wallander M, Rydén L. Rev Cardiovasc Med; 2008 Nov; 9(1):29-38. PubMed ID: 18418307 [Abstract] [Full Text] [Related]
27. Cardiovascular risk factors in type 2 diabetes: the role of hyperglycaemia. Massi-Benedetti M, Federici MO. Exp Clin Endocrinol Diabetes; 1999 Nov; 107 Suppl 4():S120-3. PubMed ID: 10522835 [Abstract] [Full Text] [Related]
28. [Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis]. Hanefeld M, Schaper F. Herz; 2004 Aug; 29(5):480-7. PubMed ID: 15340733 [Abstract] [Full Text] [Related]
38. Daily profile of plasma %CoQ10 level, a biomarker of oxidative stress, in patients with diabetes manifesting postprandial hyperglycaemia. Hasegawa G, Yamamoto Y, Zhi JG, Tanino Y, Yamasaki M, Yano M, Nakajima T, Fukui M, Yoshikawa T, Nakamura N. Acta Diabetol; 2005 Dec 01; 42(4):179-81. PubMed ID: 16382305 [Abstract] [Full Text] [Related]